Form 4: Ionis Director B. Lynne Parshall Disposes of 5,000 Shares Under 10b5-1
Rhea-AI Filing Summary
Ionis Pharmaceuticals director B. Lynne Parshall sold 5,000 shares of Ionis common stock on 08/06/2025 under a pre-established Rule 10b5-1 trading plan adopted May 6, 2025. The filings report two sales: 4,600 shares at a weighted-average price of $41.8685 (individual trade prices ranged from $41.50 to $42.36) and 400 shares at a weighted-average price of $42.6275 (individual trade prices ranged from $42.56 to $42.83). Following the reported transactions, the Form 4 shows beneficial ownership figures of 86,744 shares and 86,344 shares respectively. The reporting person is identified as a director and the sales were executed pursuant to the disclosed trading plan.
Positive
- Sales executed under a Rule 10b5-1 trading plan, indicating the transactions were pre-authorized and reduce concerns about opportunistic timing.
- Filing provides weighted-average prices and explicit price ranges and offers to supply detailed breakdowns, which supports transparency.
Negative
- None.
Insights
TL;DR: Director sales under a 10b5-1 plan are routine and signal pre-planned disposition, not necessarily a change in company outlook.
The Form 4 documents two sales by Director B. Lynne Parshall totaling 5,000 shares executed on 08/06/2025 under a Rule 10b5-1 trading plan adopted May 6, 2025. This structure typically provides an affirmative defense against insider trading claims and indicates transactions were pre-authorized. The filing also includes weighted-average prices and price ranges, and offers to provide transaction-level breakdowns on request, which supports transparency in disclosure practices. Impact on investors is limited absent additional context on relative stake size or company developments.
TL;DR: The sales are a disclosed insider disposition with clear pricing; unlikely to be materially market-moving on their own.
The Form 4 shows routine sales of 4,600 and 400 shares at weighted-average prices of $41.8685 and $42.6275, with specified price ranges. The reporting person remains a director after the transactions, and the filing includes explicit post-transaction beneficial ownership figures. Because the transactions were conducted pursuant to a documented 10b5-1 plan and the filing provides price-range transparency, these disclosures reduce uncertainty but do not by themselves convey a material operational or financial change for Ionis Pharmaceuticals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,600 | $41.8685 | $193K |
| Sale | Common Stock | 400 | $42.6275 | $17K |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.5 to $42.36 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.56 to $42.83 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
